DiaMedica Therapeutics (NASDAQ:DMAC) is a biopharmaceutical company focused on the discovery and development of novel therapies for patients suffering from chronic kidney disease and neurological disorders, aiming to address unmet medical needs in these areas. Currently, DiaMedica is traded on the NASDAQ stock exchange under the ticker symbol DMAC. The company is dedicated to advancing its lead product candidate, DM199, through clinical trials. This recombinant human protein aims to treat a range of conditions, from acute ischemic stroke to chronic kidney diseases, by leveraging its potential to improve blood flow and kidney function. DiaMedica's objective is to deliver innovative treatments that can significantly improve patients' quality of life and outcomes in areas where current options are limited or nonexistent.